Barbara Da Silva‐Tillmann

机构：AbbVie (United States)

发表论文 6 篇 · 总被引 1249 次 · h-index 4

代表论文

• ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis (2014 · New England Journal of Medicine · 被引 877)
• Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1 (2015 · JAMA · 被引 305)
• Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program (2021 · Drug Safety · 被引 44)
• Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV‐1 co‐infected patients receiving atazanavir or raltegravir ART regimens (2014 · Journal of the International AIDS Society · 被引 15)
• O163 TURQUOISE-II: SVR12 RATES OF 92–96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV) (2014 · Journal of Hepatology · 被引 4)
• Safety of ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients >= 65 Years of Age: Results From Phase 2 and 3 Trials (2014 · Hepatology · 被引 4)